Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myozyme continuation in infantile-onset Pompe disease
NCT00125879Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2005
- Primary completion
- Jun 2006
- Modality
- Replacement Enzymes
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of alglucosidase alfa in Pompe disease, sponsored by Sanofi. Primary endpoint: Long-term Safety and Efficacy at 52 weeks. Started Jun 2005; status: completed.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT00125879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125879.